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Lung cancer is the leading cause of cancer death, its
poor prognosis being related to asymptomatic develop-
ment and late detection. Hence, there is great need for
novel biomarkers that can aid in the early detection of
lung cancer. In this study, NMR-metabonomics is
applied for investigating lung cancer metabolic signa-
tures in blood plasma and urine. Biofluid samples from
lung cancer patients (n = 73) and a control healthy
g r o u p( n=5 6 )w e r ea n a l y s e db yh i g hr e s o l u t i o n
1H
NMR (500 MHz), and their spectral profiles subjected
to multivariate statistics, namely Principal Component
Analysis (PCA), Partial Least Squares Discriminant Ana-
lysis (PLS-DA) and Orthogonal Projections to Latent
Structures (OPLS)-DA. Multivariate modelling of urin-
ary spectral profiles allowed cancer and control groups
to be clearly discriminated with sensitivity and specifi-
city levels of 93 and 94%, respectively. The metabolites
giving rise to this separation were mainly creatinine,
phenylacetylglycine and N-acetylglutamine/glutamate
(elevated in patients), and hippurate and trigonelline
(reduced in patients relatively to controls). In the case
of blood plasma, good discrimination between the two
groups was also achieved, mainly due to increased levels
of lactate and LDL+VLDL, and lower levels of HDL,
glucose, acetate, histidine, glutamine and valine in can-
cer compared to healthy subjects. These results show
the promising potential of NMR metabonomics for find-
ing putative biomarkers of lung cancer in biofluids, col-
lected in a minimally invasive way, which may have
important diagnostic/prognostic impact.
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